BIVI (BioVie) Tariff Resilience Score: 5/10 (As of Jul. 08, 2026)


BIVI BioVie Inc BIVI
34 GF Score
Price $2.15
! 1 Warning Sign
View Full Analysis

What is BioVie Tariff Resilience Score?

BioVie BIVI -1.38% 34 Tariff Resilience Score is 5 as of Jul. 08, 2026. GuruFocus rates BIVI with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,367 Biotechnology companies, BioVie ranks better than 62.4% on this metric.

BioVie has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

BioVie has BioVie, a biotech firm, may face tariffs on imported research materials. However, its focus on domestic markets and potential for alternative suppliers provides some resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BioVie might have Average Resilient.

BioVie  (NAS:BIVI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BioVie Tariff Resilience Score Related Terms

BIVI vs CYCN, LNAI, CTXR: Tariff Resilience Score Comparison

For the Biotechnology subindustry, BioVie's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVie Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where BioVie's Tariff Resilience Score falls into.


BIVI
34GF Score
BioVie Inc BIVI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
BioVie (BIVI) has a Tariff Resilience Score of 5 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, BioVie ranks #514 out of 1367 companies in the Biotechnology industry, placing it in the top 37.6%.
Is BioVie's Tariff Resilience Score too high?
BioVie's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. BioVie's value of 5 is 25% above this industry median. Based on the distribution chart, BioVie ranks #514 out of 1367 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioVie has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does BioVie's Tariff Resilience Score compare to CYCN and LNAI?
According to the Biotechnology industry distribution chart, BioVie ranks #514 out of 1367 companies for Tariff Resilience Score. This puts BioVie in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. BioVie's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioVie's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVie's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVie stock overvalued right now?
BioVie (BIVI) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. BioVie's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For BioVie (BIVI), the current Tariff Resilience Score is 5 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVie Business Description

Address 680 W Nye Lane, Suite 204, Carson, NV, USA, 89703
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
34GF Score

Get the complete analysis for BIVI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.15
Price